Nature Communications (Aug 2023)

Elevated binding and functional antibody responses to SARS-CoV-2 in infants versus mothers

  • Caitlin I. Stoddard,
  • Kevin Sung,
  • Zak A. Yaffe,
  • Haidyn Weight,
  • Guillaume Beaudoin-Bussières,
  • Jared Galloway,
  • Soren Gantt,
  • Judith Adhiambo,
  • Emily R. Begnel,
  • Ednah Ojee,
  • Jennifer Slyker,
  • Dalton Wamalwa,
  • John Kinuthia,
  • Andrés Finzi,
  • Frederick A. Matsen,
  • Dara A. Lehman,
  • Julie Overbaugh

DOI
https://doi.org/10.1038/s41467-023-40554-w
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 12

Abstract

Read online

Abstract Infant antibody responses to viral infection can differ from those in adults. However, data on the specificity and function of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in infants, and direct comparisons between infants and adults are limited. Here, we characterize antibody binding and functionality against Wuhan-Hu-1 (B lineage) strain SARS-CoV-2 in convalescent plasma from 36 postpartum women and 14 of their infants infected with SARS-CoV-2 from a vaccine-naïve prospective cohort in Nairobi, Kenya. We find significantly higher antibody titers against SARS-CoV-2 Spike, receptor binding domain and N-terminal domain, and Spike-expressing cell-surface staining levels in infants versus mothers. Plasma antibodies from mothers and infants bind to similar regions of the Spike S2 subunit, including the fusion peptide (FP) and stem helix-heptad repeat 2. However, infants display higher antibody levels and more consistent antibody escape pathways in the FP region compared to mothers. Finally, infants have significantly higher levels of antibody-dependent cellular cytotoxicity (ADCC), though, surprisingly, Spike pseudovirus neutralization titers between infants and mothers are similar. These results suggest infants develop distinct SARS-CoV-2 binding and functional antibody activities and reveal age-related differences in humoral immunity to SARS-CoV-2 infection that could be relevant to protection and COVID-19 disease outcomes.